Published in Obesity and Diabetes Week, January 2nd, 2006
Under the terms of the agreement, Abbott will perform scale-up and GMP manufacturing of TRX4 for use in clinical trials, as well as supply commercial-grade material to support regulatory submissions and potential commercial launch. Financial terms were not disclosed.
"With the recent efficacy data with TRX4 in type 1 diabetes and our ongoing clinical trials in subjects with type 1 diabetes and psoriasis, this agreement positions TolerRx to ensure adequate supply of TRX4 for pivotal clinical studies and, if approved, for...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week